TWST - Twist Bioscience Corporation
Allspring Global Investments Holdings LLC purchased a new position in shares of Twist Bioscience Corporation (NASDAQ: TWST) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 455,446 shares of the company's stock, valued at approximately $22,563,000. Allspring Global Investments Holdings LLC owned approximately 0.74%
Thrivent Small Cap Growth Fund returned 25.54% during the quarter, modestly underperforming the Russell 2000 Growth Index return of 25.71%. JFrog reported stronger than expected revenue growth, reinforcing the view that customers are consolidating around JFrog as software delivery and AI-assisted development become more complex. Guidewire underperformed amid a valuation reset in higher-multiple software in addition to not raising its FY26 ARR guide due to timing of a few deals slipping to the subsequent quarter.
Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Within IT, several semiconductor holdings produced exceptional returns, with multiple positions rising more than 100% during the period. During the quarter, we initiated new positions in Entegris, Modine Manufacturing and C.H. Robinson Worldwide.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it will issue its financial results for the fiscal 2026 third quarter ended June 30, 2026, before the opening of the market on August 3, 2026. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business.
The researchers said the findings are not causal and urged more research into whether GLP-1s reduce the risk of violence. Daniel Semenza, lead author of the study and director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health, said it is important to continue studying the impact of GLP-1 medications on users' behavior and public safety as the medications become more widespread.
12,000 shares were exercised from options and sold for a total of ~$673,000 on May 12, 2026. All shares were transacted directly via option exercise and immediate sale; no indirect entities or gifts were involved.
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
This synthetic biology innovator, known for its DNA-based solutions, reported a notable insider sale amid a year of strong share gains.
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
This synthetic biology firm, known for silicon-based DNA synthesis, reported a notable insider sale following strong one-year share gains.
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist Bioscience will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026 at 10:00 am Central Time in Chicago, Illinois. The presentation will be webcast live and can be accessed by visiting the “Investor Calendar”.
Twist Bioscience Corporation (TWST) Analyst/Investor Day Transcript
DÜSSELDORF, Germany--(BUSINESS WIRE)--LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our ALiCE® platform with Twist's DNA manufacturing and automation capabilities to accelerate the design–build–test cycle for protein expression services—delivering experimental results back to customers' and partners' AI models faster. “AI can design n.
Twist Bioscience (TWST) delivered strong Q2 results, driven by AI-enabled drug discovery. NGS growth was soft due to a demand air pocket caused by a large customer. Growth is expected to rebound as this company's commercial test volumes ramp. Twist's fundamentals are likely to continue improving in coming quarters. Growth investments will create modest near-term margin headwinds though.
Twist Bioscience Corporation (NASDAQ:TWST) on Monday reported a loss for its fiscal 2026 second quarter.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value biotech company, today announced that a total of 115,279 equity awards, consisting of 101,931 restricted stock units (“RSUs”) and up to 13,348 performance stock units (“PSUs”), will be granted to 53 recently hired individuals, in each case as an inducement material to their acceptance of employment w.
Twist Bioscience Corporation (TWST) Q2 2026 Earnings Call Transcript
Twist Bioscience Corporation (NASDAQ:TWST) shares are down on Monday as the company reported its fiscal 2026 second-quarter financial results.
Twist Bioscience (TWST) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.66 per share a year ago.